Evidence-Based Medicine Guidelines
Oral Pentasa in the treatment of active Crohn's disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Oral Pentasa in the Treatment of Active Crohn's Disease." Evidence-Based Medicine Guidelines, John Wiley & Sons, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/454565/all/Oral_Pentasa_in_the_treatment_of_active_Crohn&apos.
Oral Pentasa in the treatment of active Crohn's disease. Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. https://evidence.unboundmedicine.com/evidence/view/EBMG/454565/all/Oral_Pentasa_in_the_treatment_of_active_Crohn&apos. Accessed February 11, 2026.
Oral Pentasa in the treatment of active Crohn's disease. (2025). In Evidence-Based Medicine Guidelines. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/EBMG/454565/all/Oral_Pentasa_in_the_treatment_of_active_Crohn&apos
Oral Pentasa in the Treatment of Active Crohn's Disease [Internet]. In: Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. [cited 2026 February 11]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/454565/all/Oral_Pentasa_in_the_treatment_of_active_Crohn&apos.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Oral Pentasa in the treatment of active Crohn's disease
ID - 454565
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/454565/all/Oral_Pentasa_in_the_treatment_of_active_Crohn&apos
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
